Introduction:Although advanced paternal age (APA) is increasingly scrutinized in reproductive medicine, its independent impact on embryo development and clinical outcomes remains contentious, particularly when controlling for maternal age and embryo ploidy. Methods:This retrospective cohort study analyzed 357 preimplantation genetic testing for aneuploidy (PGT-A) cycles from couples with non-advanced maternal age (≤35 years). Cycles were stratified by paternal age into three groups: <35, 35-39, and ≥40 years. We compared sperm DNA fragmentation index (DFI), embryo development metrics, and clinical outcomes across these groups. Results:Men aged ≥40 years exhibited significantly higher levels of sperm DFI compared to both younger groups (both P < 0.05). While no significant differences were observed in normal fertilization, high-quality embryo rates, or euploid blastocyst rates across paternal age groups, blastocyst development was notably impaired in the APA group. Specifically, the ≥40-year group demonstrated significantly reduced blastocyst formation rates (57.3% vs. 68.6% and 67.2%) and high-quality blastocyst formation rates (33.2% vs. 41.3% and 40.2%) compared to the <35 and 35-39 groups, respectively. Crucially, multivariate regression analysis identified DFI as an independent factor, with higher DFI significantly associated with a reduced likelihood of forming high-quality blastocysts (OR = 0.987, P = 0.046) and achieving a clinical pregnancy (OR = 0.961, P = 0.036). The sensitivity analysis demonstrates that even when examining a population of very young women (≤32 years) where the influence of maternal age on oocyte quality is expected to be minimal and uniform, the negative association between sperm DFI and embryo development potential persists (aOR = 0.980, P = 0.009). Conclusion:Our findings indicate that APA itself does not directly affect blastocyst ploidy status but is associated with significantly elevated sperm DNA fragmentation. Despite the lack of direct evidence, the detrimental effects of APA on high-quality blastocyst formation and clinical pregnancy rates are probably associated with this increase in DFI. This study underscores the critical role of sperm DNA integrity in reproductive success and suggests that DFI assessment should be considered in the clinical evaluation of older men undergoing infertility treatments.

Background Polycystic ovary syndrome (PCOS) is a disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphologic features, and PCOS is associated with infertility. PH domain Leucine-rich repeat Protein Phosphatase 1 (PHLPP1) has been shown to regulate AKT. The aim of present study is to investigate the role of PHLPP1 in PCOS. Methods The expression levels of PHLPP1 in dihydrotestosterone (DHT)-treated human ovarian granular KGN cells were determined by qRT-PCR and Western blot. PHLPP1 was silenced or overexpressed using lentivirus. Cell proliferation was detected by CCK-8. Apoptosis and ROS generation were analyzed by flow cytometry. Glycolysis was analyzed by measuring extracellular acidification rate (ECAR). Results DHT treatment suppressed proliferation, promoted apoptosis, enhanced ROS, and inhibited glycolysis in KGN cells. PHLPP1 silencing alleviated the DHT-induced suppression of proliferation and glycolysis, and promotion of apoptosis and ROS in KGN cells. PHLPP1 regulated cell proliferation and glycolysis in human KGN cells via the AKT signaling pathway. Conclusions Our results showed that PHLPP1 mediates the proliferation and aerobic glycolysis activity of human ovarian granular cells through regulating AKT signaling.

Chronic endometritis is associated with the imbalance of female reproductive tract microbiota and pathogenic microbial infection. This study aimed to identify the specific changes in the endometrial microbiome in patients with endometritis and to explore how Clostridium tyrobutyricum (C.t) influences the progression of endometritis in mice for further elucidating endometritis pathogenesis. For this purpose, endometrial tissues from 100 participants were collected and divided into positive, weakly positive, and negative groups based on CD138 levels, while endometrial microbiome differences were detected and analyzed using 16S rRNA gene sequencing. Staphylococcus aureus (S. aureus)-induced endometritis mouse model was established, followed by treatment with C.t, and inflammatory response, epithelial barrier, and TLR4/NF-κB pathway were evaluated. Results showed that α- and β-diversity was significantly lower in the positive group compared with the weakly positive or negative groups, where the negative group had more unique operational taxonomic units. The abundance of Proteobacteria was found to be increased, while that of Actinobacteria, Firmicutes, and Bacteroidetes was found to be reduced in the positive group, while the area under the curve value was found to be 0.664. Furthermore, C.t treatment resulted in the alleviation of S. aureus-induced inflammatory response, epithelial barrier damage, and activation of the TLR4/NF-κB pathway in mice. Clinical samples analysis revealed that the diversity and abundance of microbiota were altered in patients with endometritis having positive CD138 levels, while mechanistic investigations revealed C.t alleviated S. aureus-induced endometritis by inactivating TLR4/NF-κB pathway. The findings of this study are envisaged to provide a diagnostic and therapeutic potential of microbiota in endometritis.

目的:探讨3种促排卵方案对卵巢储备功能减退(DOR)患者胚胎发育的影响.方法:回顾性分析行体外受精-胚胎移植助孕治疗的DOR患者共140 个周期的临床资料,按照促排卵方案不同分为3 组,微刺激方案组40 个周期、拮抗剂方案组 40 个周期、高孕激素下促排卵(PPOS)方案组 60 个周期.比较各组患者的一般资料、激素水平、促排卵及胚胎发育情况.结果:3 组患者治疗后人绒毛膜促性腺激素(HCG)注射日激素水平比较,微刺激组 E2[(883.33±134.84)ng·L-1]低于拮抗剂组[(993.53±110.24)ng·L-1]和PPOS组[(1325.39±128.97)ng·L-1](P<0.05);3 组间促黄体素(LH)、孕激素(P)、临床妊娠率和活产率差异无统计学意义(P>0.05);PPOS组促排后其获卵数(5.67±1.16)、成熟(MⅡ)卵数(4.77±1.52)、正常受精数(3.27±0.86)、优胚数(2.73±0.69)和可利用胚胎数(3.00±0.88)均高于其他2 组(P<0.05);拮抗剂组的MⅡ数(3.03±1.07)、正常受精数(2.25±0.78)、优胚数(1.48±0.55)、可利用胚胎数(1.73±0.60)分别高于微刺激组的[(1.58±0.59)、(1.20±0.61)、(0.75±0.44)、(0.90±0.38),P<0.05];外源性促性腺激素(Gn)用药量PPOS组[(2018.27±346.17)IU)]和拮抗剂组[(2029.17±339.44)IU]均高于微刺激组[(1680.86±309.22)IU](P<0.05).结论:对于DOR患者,3 种方案中PPOS方案胚胎结局最好,其次是拮抗剂方案.

OBJECTIVES:To prospectively assess the diagnostic accuracy of MRI and transvaginal ultrasound (TVS) as well as the prognostic value of MRI for intrauterine adhesions (IUAs), using hysteroscopy as the reference standard.DESIGN:Prospective observational study.SETTING:Tertiary medical centre.PATIENT(S):Ninety-two women with amenorrhea, hypomenorrhea, subfertility, or recurrent pregnancy loss who underwent MRI and in whom Asherman's syndrome was suspected upon TVS.INTERVENTION(S):MRI and TVS were conducted approximately 1 week before hysteroscopy.METHODS:Ninety-two patients suspected of having Asherman's syndrome were examined by MRI and TVS within 7 days of an upcoming hysteroscopy. All hysteroscopy procedures were performed during the early proliferative phase of the menstrual cycle. All hysteroscopic diagnoses were performed by an experienced expert. All MRIs were read by 2 experienced, blinded radiologists.RESULTS:MRI was highly accurate (94.57%), sensitive (98.8%), and specific (42.9%) for diagnosing IUAs with a positive predictive value of 95.5% and a negative predictive value of 75%. The diagnostic values of MRI and TVS were significantly different according to McNemar tests. Junctional zone signal and junctional zone alterations correlated with the stage of IUAs.CONCLUSION:MRI is markedly superior to TVS in terms of diagnostic accuracy for IUAs, with total agreement with hysteroscopic findings. However, the main advantage of MRI is that, unlike TVS and hysterosalpingography, it can be used to assess the risk of hysteroscopy and to predict postoperative recovery and future pregnancy based on the uterine junctional zone.

目的 探讨不同精液优化处理方法对精子DNA碎片指数(DNA fragmentation index,DFI)和高DNA着色性(high DNA stainability,HDS)的影响.方法 收集30例来本生殖中心就诊男性患者的新鲜精液样本,采用上游法、密度梯度离心法和密度梯度离心联合上游法3种方法优化精液,通过精子染色质结构分析检测新鲜精液及3种优化方法处理后的精子DFI和HDS水平.结果 新鲜精液的精子DFI水平为(15.35±1.33)％,HDS水平为(2.69±0.27)％,前向运动精子百分比为(34.87±2.27)％,处理后3组的精子DFI和HDS水平均显著降低(P<0.05),前向运动精子百分比均显著提高(P<0.05).密度梯度离心联合上游组的精子DFI水平最低,前向运动精子百分比最高,且与上游组和密度梯度离心组间差异具有统计学意义(P<0.05).上游组和密度梯度离心组的精子DFI水平和前向运动精子百分比差异无统计学意义(P>0.05).密度梯度离心联合上游组和上游组的HDS水平显著低于密度梯度离心组(P<0.05),两组间差异无统计学意义(P>0.05).结论 密度梯度离心联合上游处理可极大程度降低精液中精子DFI和HDS水平,获得活力更好的精子,是一种更为理想的精液优选方法.

目的 通过对男性不育患者进行精子参数分析(SCD),探讨精子参数与患者年龄和体质指数(BMI)之间的关系.方法 收集2019年1月至2021年12月在河北省涿州市医院生殖医学科就诊的195例男性不育患者精液样本,通过赛司SCA精液分析仪进行精液常规检测,采用精子染色质扩散试验(SCD)检测精子DNA碎片指数(DFI),分析精子参数与患者年龄和BMI之间的关系.结果 与20～29岁患者相比,40岁以上患者精子浓度、总精子数和不动精子百分率(IM)指标显著提高(P<0.01、P<0.01、P=0.046);与30～39岁患者相比,40岁以上患者精子浓度和总精子数指标显著提高(P<0.01、P<0.01).与20～29和30～39岁患者相比,40岁以上患者前向运动精子百分率(PR)显著降低(P=0.003、P=0.028).随着患者体质指数的增加,与BMI<24、24～27.9患者相比,BMI>28患者精子DFI和IM显著提高(P=0.005、P=0.009;P=0.021、P=0.020);与BMI<24、24～27.9患者相比,BMI>28患者PR显著降低(P=0.008、P=0.021).相关性分析表明,精子DFI与年龄、IM、BMI呈显著正相关(r=0.176,P<0.05;r=0.499,P<0.01;r=0.199,P<0.01),与PR呈显著负相关(r=-0.504,P<0.01).结论 男性精子参数与患者年龄、BMI具有一定相关性,随着男性患者年龄和体重的增加其精子参数呈现下降趋势,临床上评估男性生育能力时应关注患者年龄和BMI指数.

子宫腺肌病是一种严重影响女性健康的良性子宫疾病,近年在40岁以下、无临床症状的以及因不孕行辅助生殖治疗的女性中检出率有所增加."子宫内膜内陷"和"细胞化生"的假说提示子宫腺肌病可能起源于子宫内膜.本文从子宫内膜的角度出发对子宫腺肌病的早期子宫内膜变化进行总结,进而对子宫腺肌病的致病因素有综合了解,以便更加深入的认识子宫腺肌病对女性的影响.

目的:分析反复种植失败患者宫腔镜下内膜微刺激术后当月移植的妊娠结局.方法:选择某医院行宫腔镜检查反复种植失败的不孕症患者204例,于月经第2天给予雌二醇片/雌二醇地屈孕酮片复合包装(芬吗通)的红片口服,每次2 mg、每天2次,直至宫腔镜检查当日.纳入宫腔镜检查和病理结果均正常的99例,分为当月移植组31例和次月移植组68例.收集入组病例的一般资料,包括年龄、不孕时间、基础窦卵泡计数(AFC)、体质量指数(BMI)、抗苗勒管激素(AMH)值、反复种植失败次数、优质胚胎比例、移植囊胚比例等进行汇总分析.均给予宫腔镜下内膜微刺激术,以小刮匙轻刮宫腔1～2周.当月移植组术后继续给予芬吗通(红片)行人工周期准备内膜;次月移植组术后适时给予孕激素撤退来月经,次月行人工周期准备内膜,适时行移植术.两组均根据内膜厚度和分型调整用药剂量决定移植日,监测指标包括转化日内膜厚度、内膜分型、血清雌二醇水平以及雌二醇作用内膜时间;根据相应监测数值,适时转化内膜,行胚胎移植术.移植术后10～14天行血β-人绒毛膜促性腺激素(β-HCG)检测,移植术后25天行阴道超声检查,确定是否临床妊娠.电话随访分娩及新生儿情况.结果:(1)两组基础AFC、BM1及优质胚胎和移植囊胚构成比较,均差异不显著(P＞0.05).当月移植组年龄、不孕时间及反复种植失败次数,均非常显著高于次月移植组(P＜0.01);AMH值非常显著低于次月移植组(P＜0.01).(2)当月移植组临床妊娠率51.61％(16/31),流产率12.50％(2/16),活产率45.16％(14/31),新生儿男女比例9:10;次月移植组临床妊娠率54.41％(37/68),流产率13.33％(5/37),活产率44.83％(29/68),新生儿男女比例18:16;两组上述指标比较,均差异不显著(P＞0.05).(3)当月移植组转化日雌二醇作用内膜时间,非常显著低于次月移植组(P＜0.01);两组转化日血清雌二醇水平及内膜厚度、B型内膜构成比较,均差异不显著(P＞0.05).结论:宫腔镜下内膜微刺激术后当月移植,可以获得与次月移植相当的临床妊娠率和活产率,为反复种植失败的治疗提供了新的选择.

Background Despite the widespread use of oxygen (O 2 ) in intrauterine resuscitation, the obstetric scientists’ understanding of O 2 therapy is full of contradictions. We tested the hypothesis that higher maternal arterial partial pressure of oxygen (PO 2 ) is associated with higher umbilical cord venous PO 2 (UvPO 2 ). Methods This is a planned secondary analysis of a randomised controlled trial (RCT), 443 normal women were 1:1 randomly allocated to receive 2 L/min O 2 or room air from the onset of second stage to delivery. We reported that maternal 2 L/min O 2 exposure cannot affect the umbilical cord arterial pH or the fetal heart rate (FHR) pattern. In 217 non-random samples, we found 2 L/min O 2 exposure increased the maternal arterial PO 2 to the median 150 mmHg (hemoglobin would be saturated). The primary outcome for this analysis was UvPO 2 in these non-random samples. Results There were no significant differences between the O 2 group ( N = 107) and the control group ( N = 110) in the UvPO 2 (median 30.2, interquartile 25.4–35.2 versus median 28.3, interquartile 23.4–35.3, mmHg, P = 0.379). There were also no significant differences between room air and different percentiles of O 2 exposure duration (< 25th, ≧ 25th < 50th, ≧ 50th < 75th, ≧ 75th percentile) in the UvPO 2 . Conclusions Maternal O 2 exposure at super-physiological levels (median arterial blood PO 2 150 mmHg) in normal labor may not change the UvPO 2 . Clinical trial registration ClinicalTrials.gov NCT02221440 , first posted in 20 August 2014.

慢性子宫内膜炎(CE)与女性生殖预后密切相关.目前认为CE是一种子宫内膜结构和功能被破坏的持续性炎症过程,由于局部内膜炎性细胞浸润和炎症介质渗出会改变子宫内膜微环境,影响子宫内膜容受性,不利于胚胎着床,可能是反复移植失败、复发性流产的原因之一.多年来CE由于临床症状轻微、缺乏特异性而被临床医生所忽视,因此本文就CE的微生物学、免疫学以及CE可能影响女性妊娠结局的相关机制进行综述,以期为CE相关不孕症的早期诊断及治疗提供理论依据.

TORCH 是弓形体(toxoplasma gondii,TOX)、风疹病毒(rubella virus,RV)、巨细胞病毒(cytomegalovirus, CMV)、单纯疱疹病毒(herpes simplex virus,HSV)及其他病原体如梅毒螺旋体(treponema pallidum,TP)、带状疱疹病毒(varicella-zoster virus,VZV)、微小病毒 B19 (human parvovirus B19,HPV B19)等英文名称首字母缩写组合而成.TORCH 病原微生物可以通过胎盘垂直传播,引起宫内感染,造成早产、流产、死胎或胎儿畸形;通过产道感染新生儿,造成新生儿多系统、多脏器损伤和智力障碍等.在低收入和中等收入国家, TORCH 感染是产前、围产期和产后发病率和死亡率增加的主要原因[1].孕前、孕期 TORCH 筛查一直是围产保健的重要项目[2].根据不断更新的临床证据,规范 TORCH 筛查,明确孕前免疫状况、孕期母胎是否感染、何时感染、胎儿是否受到损害以及是否能继续妊娠等问题,一直是临床关注的核心[3-11].目前已有很多国家和地区将 TORCH 筛查涉及的病原体列入孕期检查项目,颁布了相关指南[3-9].

目的 本研究以ICSI后未成熟卵母细胞为研究对象,分析比较卵母细胞不同发育阶段冷冻对其后续效果的影响,评估ICSI后未成熟卵母细胞的利用价值.方法 未成熟卵母细胞直接成熟培养(新鲜组)与玻璃化冷冻后成熟培养(冷冻组)的成熟率,并利用孤雌激活的方法比较卵母细胞的发育潜力.结果 发现新鲜组与冷冻组体外培养卵母细胞成熟率、 受精率、 卵裂率、 优质胚胎率和囊胚率均无差异(P>0.05).但两组的GV期卵母细胞成熟率低于MI期(P<0.05),且冷冻组的GV期卵母细胞受精率低于MI期(P<0.05).不过裸卵体外成熟培养效果欠佳,特别是对GV期卵母细胞,体外成熟培养后的卵母细胞发育潜力低下,无囊胚形成.结论 ICSI后未成熟卵母细胞的冷冻对卵母细胞的发育潜力没有明显影响,但体外成熟培养的卵母细胞发育潜力低下,有待进一步提高体外成熟培养技术.

目的 比较拟行体外受精-胚胎移植(IVF-ET)的卵巢低反应(POR)患者黄体期应用人绝经期促性腺激素(human menopausal gonadotropin,HMG)或促卵泡素(FSH)进行超促排卵的临床效果.方法 125例拟行IVF-ET的POR患者,随机分为A组85例、B组40例.A、B组分别采用HMG、FSH超促排卵,自然周期阴道超声可见黄体的当日或次日开始应用人HMG、FSH,HMG起始剂量150～300 IU/天,FSH起始剂量150～300 IU/d,监测卵泡发育情况个体化调整用药剂量,至少1～2个卵泡直径≥17～18 mm时停用HMG、FSH,给予绒毛膜促性腺激素(HCG)5000～10000 IU,诱导排卵.HCG注射日抽取两组静脉血,化学发光免疫方法检测两组血清性激素(FSH、LH、P、E2),观察并记录两组HCG注射日≥10 mm的卵泡数、Gn用药总量、Gn用药天数,两组均行解冻周期移植.观察两组促排效果及妊娠结局(获卵率、正常受精率、Day3优胚率、妊娠率、临床妊娠率、流产率).结果 两组HCG日血清FSH、LH、P、E2水平及≥10 mm卵泡数、Gn用药总量、Gn用药天数间比较差异均无统计学意义(P均>0.05).两组获卵率、正常受精率、Day3优胚率、妊娠率、临床妊娠率、流产率比较差异均无统计数学意义(P均>0.05).结论 拟行IVF-ET的POR患者黄体期应用HMG、FSH行超促排卵在IVF-ET中效果差异不大.

目的:观察甲氨蝶呤联合米非司酮治疗产后胎盘残留的临床疗效.方法:选择某军队医院收治的产后胎盘残留84例,随机分为观察组和对照组各42例.对照组采用甲氨蝶呤单药治疗,观察组采用甲氨蝶呤联合米非司酮治疗;比较两组临床疗效,以及治疗前后血人绒毛膜促性腺激素(HCG)水平与C反应蛋白(CRP)水平变化情况和不良反应发生情况.结果:(1)观察组治疗前血HCG水平为(104.39±91.59) mU/ml,与对照组的(104.58±92.01)mU/ml比较,差异不显著(P＞0.05);观察组治疗1个月后血HCG水平降至(4.20±3.10) mU/ml,与对照组的(12.52±6.19) mU/ml比较,差异非常显著(P＜0.01).(2)观察组治疗前血清CRP水平为(64.25±11.05) mg/L,与对照组的(63.92±11.12) mg/L比较,差异不显著(P＞0.05);观察组治疗1个月后血清CRP水平降至(10.52±1.52) mg/L,与对照组的(17.33±6.26) mg/L比较,差异非常显著(P＜0.01).(3)两组均治疗1个月后评定临床疗效,观察组治愈15例(35.7％),有效20例(47.6％),无效7例(16.7％),总有效35例(83.3％);对照组治愈10例(23.8％),有效14例(33.3％),无效18例(42.9％),总有效24例(57.1％);两组总有效率比较,差异非常显著(P＜0.01).(4)对照组治疗期间出现恶心呕吐3例(7.1％)、肝功能异常2例(4.8％)、肾功能异常2例(4.8％),观察组治疗期间仅出现恶心呕吐2例(4.8％);两组不良反应发生率比较,差异不显著(P＞0.05).结论:甲氨蝶呤联合米非司酮治疗产后胎盘残留临床疗效满意,能够有效降低血HCG水平与血清CRP水平,且较安全.

宫腔粘连,又称Asherman综合征,是由多种病因导致的子宫内膜基底层损伤,宫腔部分或全部闭塞的一组疾病,临床表现为月经异常、不孕及反复流产.宫腔镜下宫腔粘连分解术(transcervical resection of uterine adhesion,TCRA)是主要的治疗方式,也是最理想的手术方法,但术后粘连复发率高,中重度宫腔粘连患者TCRA后再粘连的发生率高达20.0％～62.5％[1],因此,预防术后再粘连是治疗成功的关键.本试验采用随机对照试验(RCT),研究在TCRA后放置三角子宫球囊预防宫腔再粘连的临床疗效以及患者远期的妊娠结局,旨在为三角子宫球囊在宫腔粘连治疗中的应用提供依据.

目的 探讨一次不明原因流产与精子DNA损伤的关系.方法 收集有一次不明原因流产史的患者作为实验组,同时以有正常妊娠史的患者为对照组,分别比较两组男方年龄、精子密度、精子活力、精液量和精子DNA断裂指数有无差异.以SPSS 16.0为统计软件,进行独立样本的t检验.结果 两组的精液量、精子密度及活力均无差异,实验组男方年龄小于对照组(P＜0.05),但实验组的DFI要高于对照组(P＜0.01).结论 本研究对照组年龄高于实验组,而DFI正好相反.这说明不明原因的自发流产与男方精子DFI密切相关,随着DF1的增加,流产风险增加.

目的:比较PPOS方案与拮抗剂方案对卵巢低反应患者行IVF-ET助孕治疗的临床效果,探讨两种超促排卵方案在卵巢低反应(POR)患者中的疗效差异.方法:回顾分析2014年5年至2018年5月在解放军总医院第六医学中心辅助生殖医学中心行IVF-ET助孕治疗的POR患者的临床资料,根据促排卵方案不同分为PPOS组(实验组,48个周期)和拮抗剂组(对照组,67个周期).比较两组患者的基本情况、助孕效果及妊娠结局.结果:两组患者的基本情况、基础激素水平、HCG日激素水平(FSH、P、E 2)、HCG日≥10mm卵泡数、获卵数、正常受精数、Day3优胚数、可用胚胎数、妊娠率、临床妊娠率、流产率比较,差异均无统计学意义(P>0.05).PPOS组的HCG日血清LH水平明显低于拮抗剂组,差异有统计学意义[(2.88±2.56)mIU/ml vs(4.51±4.26)mIU/ml,P<0.05];PPOS组Gn用药总量、用药天数均多于拮抗剂组,差异有统计学意义[(2210.42±766.88)IU vs(1747.01±764.98)IU;(10.88±3.21)d vs(9.12±3.14)d,P<0.05].PPOS方案组的获卵率、正常受精率、Day3优胚率、妊娠率、临床妊娠率与拮抗剂方案组相比无统计学差异,但总体上,均为PPOS组更理想(81.8％vs 71.1％、61.2％vs 58.2％、74.3％vs 73.2％、29.6％vs 16.3％、18.5％vs 10.5％).PPOS组的周期取消率(14.58％)低于拮抗剂方案组(34.33％),差异有统计学意义(P<0.05).结论:PPOS方案能更有效控制早发LH峰,使周期取消率更低,降低了治疗费用,有较好的临床价值.

近年来,随着不孕症患者人数增加、生殖医学领域的迅猛发展、辅助生殖技术的飞速进步,试管婴儿技术已逐渐被民众接受.辅助生殖技术虽涉及不同的促排卵方案,但最终都是为了获得适当数量的卵子,得到更多优质胚胎,最终达到临床妊娠的目的 .目前个体化的促排卵方案已被广泛应用于各种不孕患者,成功率也正逐步提高.研究表明辅助生殖技术增加子代出生缺陷风险,但具体原因及影响因素仍不明确.本文对近年来辅助生殖技术相关的子代出生缺陷报道进行综述.